Lipid nanoparticles targeting tumor-associated macrophages, co-delivery method and application in tumor immunotherapy
By designing lipid nanoparticles (ipLNPs) that target tumor-associated macrophages, we achieved highly efficient targeted delivery to CD206+M2 tumor-associated macrophages and synergistically delivered multiple nucleic acid molecules, restoring T cell function, enhancing the anti-tumor ability of macrophages, and reshaping the tumor microenvironment. This solved the problems of insufficient targeting and multifunctional delivery in existing technologies, and significantly improved the efficacy of immunotherapy.
Patent Information
- Application Number
- CN202610338216.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-03-19
- Publication Date
- 2026-06-19
AI Technical Summary
Existing technologies cannot achieve precise targeted delivery to tumor-associated macrophages in solid tumors and lack the ability to synergistically deliver multifunctional nucleic acids, resulting in poor immunotherapy efficacy. Existing lipid nanoparticle systems have insufficient targeting in the tumor microenvironment and are unable to simultaneously relieve immunosuppression, improve immune infiltration, and reshape the tumor microenvironment.
A lipid nanoparticle (ipLNP) targeting tumor-associated macrophages was designed. By assembling SM-102, cholesterol, DSPC, and DSPE-PEG2000-Mannose in a specific ratio, it achieves efficient targeted delivery to CD206+M2 tumor-associated macrophages. Simultaneously, it loads anti-PD-L1 antibody-encoded mRNA, HER2-CAR mRNA, and FN1 gene-targeting sgRNA, realizing the synergistic delivery of multifunctional nucleic acids and gene editing.
It achieves precise regulation of tumor-associated macrophages, restores T cell function, enhances the anti-tumor ability of macrophages, reshapes the tumor microenvironment, significantly improves the efficacy of immunotherapy, and reduces off-target toxicity.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
